Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | DHFR | P00374 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20482096 | 1.00 | SLC6A3 (0.55) | SLC6A3SLC6A2SLC6A4HIF1AHSD17B10 | |
| SCHEMBL13293156 | 1.00 | SLC6A3 (0.55) | SLC6A3SLC6A2SLC6A4HIF1AHSD17B10 | |
| SCHEMBL20440763 | 1.00 | SLC6A3 (0.55) | SLC6A3SLC6A2SLC6A4HIF1AHSD17B10 | |
| SCHEMBL5177411 | 1.00 | SLC6A3 (0.55) | SLC6A3SLC6A2SLC6A4HIF1AHSD17B10 | |
| SCHEMBL9872556 | 1.00 | SLC6A3 (0.55) | SLC6A3SLC6A2SLC6A4HIF1AHSD17B10 | |
| SCHEMBL20439223 | 1.00 | SLC6A3 (0.55) | SLC6A3SLC6A2SLC6A4HIF1AHSD17B10 | |
| SCHEMBL20482420 | 1.00 | SLC6A3 (0.55) | SLC6A3SLC6A2SLC6A4HIF1AHSD17B10 | |
| SCHEMBL20482130 | 1.00 | SLC6A3 (0.55) | SLC6A3SLC6A2SLC6A4HIF1AHSD17B10 | |
| Hydrochloric Acid SCHEMBL20482410 | 0.98 | SLC6A3 (0.54) | SLC6A3SLC6A2SLC6A4HIF1AHSD17B10 | |
| Hydrochloric Acid SCHEMBL3552029 | 0.98 | SLC6A3 (0.54) | SLC6A3SLC6A2SLC6A4HIF1AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110831951-B | Multiple coupling and oxidation process | 罗氏创新中心哥本哈根有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-109311925-B | Enhanced coupling of sterically defined oxaazaphospholane phosphoramidite monomers to nucleosides or oligonucleotides | 罗氏创新中心哥本哈根有限公司 | 2022-06-03 | — | — | CN | disclosed |
| CN-110831951-A | Multiple coupling and oxidation process | 罗氏创新中心哥本哈根有限公司 | 2020-02-21 | — | — | CN | disclosed |
| CN-110325512-A | The method for being used to prepare chiral pyrrolidine -2- base carbinol derivatives | 豪夫迈·罗氏有限公司 | 2019-10-11 | — | — | CN | disclosed |
| WO-2018153820-A1 | PROCESS FOR THE PREPARATION OF CHIRAL PYROLLIDINE-2-YL- METHANOL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2018-08-30 | — | — | WO | disclosed |
| US-7666888-B2 | Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1 | AMGEN INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-7666888-B2 | Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1 | AMGEN INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-20080021022-A1 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 | AMGEN INC. | 2008-01-24 | — | — | US | disclosed |
| US-20080021022-A1 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 | AMGEN INC. | 2008-01-24 | — | — | US | disclosed |
| EP-1478645-A2 | QUINOLINONE DERIVATIVES FOR TREATING CELL PROLIFERATION RELATED DISORDERS | Amgen Inc. (US) | 2004-11-24 | — | — | EP | disclosed |
| WO-2003066630-A2 | QUINOLINONE DERIVATIVES FOR TREATING CELL PROLIFERATION RELATED DISORDERS | AMGEN INC. (US) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021022-A1 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 | HSD17B1, HSD11B1, HSD17B11 | SLC6A3 2642/4885SLC6A2 3032/4885SLC6A4 1532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.